<PAGE>
THE SECURITIES EVIDENCED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") OR UNDER ANY APPLICABLE STATE
SECURITIES LAW AND MAY NOT BE TRANSFERRED, SOLD OR OTHERWISE DISPOSED OF IN THE
ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR AN
OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION
STATEMENT IS NOT REQUIRED UNDER THE SECURITIES ACT AND THE RULES AND REGULATIONS
PROMULGATED THEREUNDER OR UNDER APPLICABLE STATE SECURITIES LAWS.
WARRANT CERTIFICATE
-------------------
December 26, 2000
To Purchase 600,846 Shares of Common Stock of:
CYTOMEDIX, INC.
THIS IS TO CERTIFY THAT, for value received, CURATIVE HEALTH SERVICES, INC.
or its assigns (the "Holder"), is entitled to purchase from Cytomedix, Inc., a
Delaware corporation (the "Company"), Six Hundred Thousand, Eight Hundred
Forty-Six (600,846) shares of the Company's common stock, par value $.0001 per
share (the "Common Stock"), on the terms and conditions hereinafter set forth.
I. GRANT OF WARRANT
1.1 GRANT AND VESTING. The Company hereby grants to the Holder a warrant to
purchase up to 600,846 shares of Common Stock (this "Warrant") at a purchase
price equal to the lesser of $.50 per share of Common Stock, as adjusted as
provided herein (the "Fixed Exercise Price"), or a price per share equal to the
average of the three lowest intraday sale prices as reported by Bloomberg
Financial Markets or an equivalent, reliable reporting service mutually
acceptable to and hereafter designated by the Holder and the Company (as
equitably adjusted for stock splits or combinations or other events referenced
in Article II hereof) during the twenty (20) trading days immediately preceding
the date on which this Warrant is exercised (the "Market Exercise Price"). This
Warrant shall vest as to all 600,846 shares of Common Stock immediately upon the
Holder's funding of the principal sum of $1,682,571 to the Company pursuant to
the terms of that certain 10% Convertible Secured Promissory Note payable by the
Company to Holder dated as of the date hereof (the "Note"). The shares of Common
Stock, or other securities for which this Warrant may be exercised as a result
of transactions contemplated by Article II, are referred to as the "Warrant
Shares." The term "Warrants" shall mean this Warrant and the other warrants
issued pursuant to that certain Securities Purchase Agreement of even date
herewith by and among the Company and the Buyers listed on the signature pages
thereof (the "Securities Purchase Agreement").
<PAGE>
1.2 EXERCISE PERIOD. This Warrant shall be exercisable commencing on the
date of original issuance of this Warrant (the "Exercisability Date") and
continue to be exercisable for the period (the "Exercise Period") until 5:00
p.m., Eastern Standard Time, on the date that is ten (10) years from the date of
this Warrant.
1.3 SHARES TO BE ISSUED; RESERVATION OF SHARES. The Company covenants and
agrees that (a) all of the securities issuable upon the exercise of this Warrant
in accordance with the terms hereof will, upon issuance in accordance with the
terms hereof and payment of the Exercise Price therefor, be duly authorized,
validly issued and outstanding, fully paid and non-assessable, and free from all
taxes, liens and charges with respect to the issuance thereof, (b) the Company
will cause during the Exercise Period, there to be authorized and reserved a
sufficient number of securities to provide for the exercise of this Warrant in
full, and (c) the Company shall promptly secure the listing of the shares of
Common Stock issuable upon exercise of the Warrant upon each national securities
exchange or automated quotation system, if any, upon which shares of Common
Stock are then listed (subject to official notice of issuance upon exercise of
this Warrant) and shall maintain, so long as any other shares of Common Stock
shall be so listed, such listing of all shares of Common Stock from time to time
issuable upon the exercise of this Warrant; and the Company shall so list on
each national securities exchange or automated quotation system, as the case may
be, and shall maintain such listing of, any other shares of capital stock of the
Company issuable upon the exercise of this Warrant if and so long as any shares
of the same class shall be listed on such national securities exchange or
automated quotation system.
II. ADJUSTMENTS TO WARRANT
2.1 STOCK SPLITS AND COMBINATIONS. If the Company shall combine all of its
outstanding shares of Common Stock into a smaller number of shares, the number
of Warrant Shares shall be proportionately decreased and the Fixed Exercise
Price in effect immediately prior to such combination shall be proportionately
increased, as of the effective date of such combination, as follows: (a) the
number of Warrant Shares purchasable immediately prior to the effective date of
such combination shall be adjusted so that the Holder of this Warrant, if
exercised on or after that date, shall be entitled to receive the number and
kind of Warrant Shares which the Holder of this Warrant would have owned and
been entitled to receive as a result of the combination had the Warrant been
exercised immediately prior to that date, and (b) the Fixed Exercise Price in
effect immediately prior to such adjustment shall be adjusted by multiplying
such Fixed Exercise Price by a fraction, the numerator of which is the aggregate
number of shares of Common Stock purchasable upon exercise of this Warrant
immediately prior to such adjustment, and the denominator of which is the
aggregate number of shares of Common Stock purchasable upon exercise of this
Warrant immediately thereafter. If the Company shall subdivide all of its
outstanding shares of Common Stock, the number of Warrant Shares shall be
proportionally increased and the Fixed Exercise Price in effect prior to such
subdivision shall be proportionately decreased, as of the effective date of such
subdivision, as follows: (a) the number of Warrant Shares purchasable upon the
exercise of this Warrant immediately prior to the effective date of such
subdivision, shall be adjusted so that the Holder of this Warrant, if exercised
on or after that date, shall be entitled to receive the number and kind of
Warrant Shares which the Holder of this Warrant would have owned and been
entitled to
2
<PAGE>
receive as a result of the subdivision had the Warrant been exercised
immediately prior to that date, and (b) the Fixed Exercise Price in effect
immediately prior to such adjustment shall be adjusted by multiplying the Fixed
Exercise Price by a fraction, the numerator of which is the aggregate number of
shares of Common Stock purchasable upon exercise of this Warrant immediately
prior to such adjustment, and the denominator of which is the aggregate number
of shares of Common Stock purchasable upon exercise of this Warrant immediately
thereafter. A like and equitable adjustment shall be made in the event that a
stock combination or subdivision is effectuated and the number of Warrant Shares
issued hereunder is to be determined by reference to the Market Exercise Price.
2.2 STOCK DIVIDENDS AND DISTRIBUTIONS. If the Company shall fix a record
date for the holders of its Common Stock entitled to receive a dividend or other
distribution payable in additional shares of Common Stock, then the number of
Warrant Shares shall be proportionately increased and the Fixed Exercise Price
in effect prior to the time of such issuance or the close of business on such
record date shall be proportionately decreased, as of the time of such issuance,
or in the event such record date is fixed, as of the close of business on such
record date, as follows: (a) the number of Warrant Shares purchasable
immediately prior to the time of such issuance or the close of business on such
record date shall be adjusted so that the Holder of this Warrant, if exercised
after that date, shall be entitled to receive the number and kind of Warrant
Shares which the Holder of this Warrant would have owned and been entitled to
receive as a result of the dividend or distribution had the Warrant been
exercised immediately prior to that date, and (b) the Fixed Exercise Price in
effect immediately prior to such adjustment shall be adjusted by multiplying
such Fixed Exercise Price by a fraction, the numerator of which is the aggregate
number of shares of Common Stock purchasable upon exercise of this Warrant
immediately prior to such adjustment, and the denominator of which is the
aggregate number of shares of Common Stock purchasable upon exercise of this
Warrant immediately thereafter. A like and equitable adjustment shall be made in
the event that a stock dividend or distribution is effectuated and the number of
Warrant Shares issued hereunder is to be determined by reference to the Market
Exercise Price.
2.3 OTHER DIVIDENDS AND DISTRIBUTIONS. If the Company shall fix a record
date for the holders of Common Stock entitled to receive a dividend or other
distribution payable in securities of the Company other than shares of Common
Stock, then lawful and adequate provision shall be made so that the Holder of
this Warrant shall be entitled to receive upon exercise of this Warrant, for the
applicable exercise price in effect prior thereto, in addition to the number of
Warrant Shares immediately theretofore issuable upon exercise of this Warrant,
the kind and number of securities of the Company which the Holder would have
owned and been entitled to receive had the Warrant been exercised immediately
prior to that date.
2.4 RECLASSIFICATION, EXCHANGE AND SUBSTITUTION. If the Common Stock is
changed into the same or a different number of shares of any class or classes of
stock, whether by recapitalization, reclassification or otherwise (other than by
a subdivision or combination of shares or stock dividend or a reorganization,
merger, consolidation or sale of assets provided for elsewhere in this Article
II), then the Holder of this Warrant shall be entitled to receive upon exercise
of this Warrant, in lieu of the Warrant Shares immediately theretofore issuable
upon exercise of this Warrant, for the aggregate exercise price in effect prior
thereto, the kind and amount of stock and other securities and property
receivable upon such recapitalization, reclassification or other change, by the
holders of the number
3
<PAGE>
of shares of Common Stock for which the Warrant could have been exercised
immediately prior to such recapitalization, reclassification or other change (in
any event, subject to further anti-dilution protection as provided in this
Section 2).
2.5 REORGANIZATIONS, MERGERS, CONSOLIDATIONS OR SALES OF ASSETS. If any of
the following transactions (each, a "Special Transaction") shall become
effective: (a) a capital reorganization, share exchange or exchange offer (other
than a recapitalization, subdivision, combination, reclassification or exchange
of shares provided for elsewhere in this Article II), (b) a consolidation or
merger of the Company with and into another entity, or (c) a sale or conveyance
of all or substantially all of the Company's assets, then as a condition of any
Special Transaction, lawful and adequate provision shall be made so that the
Holder of the Warrant shall thereafter have the right to purchase and receive
upon exercise of this Warrant, in lieu of the Warrant Shares immediately
theretofore issuable upon exercise of this Warrant, for the applicable exercise
price in effect immediately prior to such event, such shares of stock, other
securities, cash or other assets as may be issued or payable in and pursuant to
the terms of such Special Transaction to the holders of shares for which this
Warrant could have been exercised immediately prior to such Special Transaction;
provided, however, that notwithstanding anything to the contrary herein, that
upon consummation of the transactions contemplated by the Exchange Agreement (as
defined below), this Warrant shall be exercisable for shares of common stock of
Cytomedix NV. In connection with any Special Transaction, appropriate provision
shall be made with respect to the rights and interests of the Holder of this
Warrant to the end that the provisions of this Warrant (including, without
limitation, provisions for adjustment of the applicable exercise price and the
number of Warrant Shares issuable upon the exercise of this Warrant), shall
thereafter be applicable, as nearly as may be practicable, to any shares of
stock, other securities, cash or other assets thereafter deliverable upon the
exercise of this Warrant. The Company shall not effect any Special Transaction
unless prior to, or simultaneously with the closing thereof, the successor
entity and the issuer of the securities into which this Warrant is exercisable
(if other than the Company), if any, resulting from such Special Transaction
shall assume by a written instrument executed and mailed by certified mail or
delivered to the Holder of this Warrant at the address of the Holder appearing
on the books of the Company, the obligation of the Company or such successor
corporation to deliver to the Holder such shares of stock, securities, cash or
other assets, as in accordance with the foregoing provisions, which the Holder
shall have the right to purchase.
2.6 OTHER ISSUANCES. In the event that the Company shall at any time after
the Exercisability Date issue any shares of Common Stock, including shares of
Common Stock issued or issuable upon the conversion or exercise of securities
convertible into or exercisable for Common Stock, without consideration or at a
price per share ("Issuance Price") less than the then applicable exercise price,
then, in each and any such event (an "Adjustment Event"), (a) the number of
Warrant Shares purchasable immediately prior thereto (the "Initial Number")
shall be increased so that the Holder shall be entitled, upon exercise of this
Warrant, to receive the number of shares of Common Stock determined by
multiplying the Initial Number by a fraction, the numerator of which shall be
the number of shares of Common Stock outstanding immediately prior to such
Adjustment Event plus the number of additional shares of Common Stock issued in
such Adjustment Event and the denominator of which shall be the number of shares
of Common Stock outstanding immediately
4
<PAGE>
prior to such Adjustment Event plus the number of shares of Common Stock which
the aggregate Issuance Price of the total number of shares of Common Stock
issued in such Adjustment Event would purchase at the then applicable exercise
price; provided, however, that no adjustment shall be made for the issuance of
shares of Common Stock in connection with a Special Transaction, as described in
Section 2.5; and the applicable Fixed Exercise Price shall be reduced to the
Issuance Price.
2.7 LIQUIDATION. If the Company shall, at any time prior to the end of the
Exercise Period, dissolve, liquidate or wind up its affairs, the Holder shall
have the right, but not the obligation, to exercise this Warrant. Upon such
exercise, the Holder shall have the right to receive, in lieu of the shares of
Common Stock that the Holder otherwise would have been entitled to receive upon
such exercise, the same kind and amount of assets as would have been issued,
distributed or paid to the Holder upon any such dissolution, liquidation or
winding up with respect to such shares of Common Stock had the Holder been the
holder of record of such shares of Common Stock receivable upon exercise of this
Warrant on the date for determining those entitled to receive any such
distribution. If any such dissolution, liquidation or winding up results in any
cash distribution in excess of the applicable exercise price, the Holder may, at
the Holder's option, exercise this Warrant without making payment of the
applicable exercise price and, in such case, the Company shall, upon
distribution to the Holder, consider the applicable exercise price, to have been
paid in full, and in making settlement to the Holder shall deduct an amount
equal to the applicable exercise price, from the amount payable to the Holder.
2.8 NOTICE. Whenever this Warrant or the number of Warrant Shares is to be
adjusted as provided herein, the Company shall forthwith as soon as reasonably
practicable, and in any case within three (3) business days of such adjustment,
and in any case within three (3) business days of such adjustment, cause to be
sent to the Holder a notice stating in reasonable detail the relevant facts and
any resulting adjustments and the calculation thereof.
2.9 FRACTIONAL INTERESTS. The Company shall not be required to issue
fractions of shares of Common Stock upon the exercise of this Warrant. If any
fraction of a share of Common Stock would be issuable upon the exercise of this
Warrant, the Company shall, upon such issuance, purchase such fraction for an
amount in cash equal to the current value of such fraction, computed on the
basis of the last reported closing price of the Common Stock on the securities
exchange or quotation system on which the shares of Common Stock are then listed
or traded, as the case may be, if any, on the last business day prior to the
date of exercise upon which such a sale shall have been effected, or, if the
Common Stock is not so listed or traded on an exchange or quotation system, as
the Board of Directors of the Company may in good faith determine.
2.10 EFFECT OF ALTERNATE SECURITIES. If at any time, as a result of an
adjustment made pursuant to this Article II, the Holder of this Warrant shall
thereafter become entitled to receive any securities of the Company other than
shares of Common Stock, then the number of such other securities receivable upon
exercise of this Warrant shall be subject to adjustment from time to time on
terms as nearly equivalent as practicable to the provisions with respect to
shares of Common Stock contained in this Article II.
5
<PAGE>
2.11 SUCCESSIVE APPLICATION. The provisions of this Article II shall apply
from time to time to successive events covered by this Article II. Upon the
occurrence of any event contemplated by this Article II, all references to
Common Stock, to the Company and to other defined terms shall be equitably
adjusted to protect the interests of the Holder.
2.12 OTHER NOTICES. In case at any time:
(I) the Company shall declare any dividend upon the Common Stock
payable in shares of stock of any class or make any other distribution
(including dividends or distributions payable in cash out of retained earnings)
to the holders of the Common Stock;
(II) the Company shall offer for subscription pro rata to the holders
of the Common Stock any additional shares of stock of any class or other rights;
(III) there shall be any capital reorganization of the Company, or
reclassification of the Common Stock, or consolidation or merger of the Company
with or into, or sale of all or substantially all its assets to, another
corporation or entity; or
(IV) there shall be a voluntary or involuntary dissolution, liquidation
or winding-up of the Company;
then, in each such case, the Company shall give to the holder of this Warrant
(a) notice of the date on which the books of the Company shall close or a record
shall be taken for determining the holders of Common Stock entitled to receive
any such dividend, distribution, or subscription rights or for determining the
holders of Common Stock entitled to vote in respect of any such reorganization,
reclassification, consolidation, merger, sale, dissolution, liquidation or
winding-up and (b) in the case of any such reorganization, reclassification,
consolidation, merger, sale, dissolution, liquidation or winding-up, notice of
the date (or, if not then known, a reasonable approximation thereof by the
Company) when the same shall take place. Such notice shall also specify the date
on which the holders of Common Stock shall be entitled to receive such dividend,
distribution, or subscription rights or to exchange their Common Stock for stock
or other securities or property deliverable upon such reorganization,
reclassification, consolidation, merger, sale, dissolution, liquidation, or
winding-up, as the case may be. Such notice shall be given at least twenty (20)
business days prior to the record date or the date on which the Company's books
are closed in respect thereto. Failure to give any such notice or any defect
therein shall not affect the validity of the proceedings referred to in clauses
(i), (ii), (iii) and (iv) above.
2.13 EXCEPTION TO ADJUSTMENTS. Notwithstanding anything herein or in any
Note to the contrary, no adjustment to the Fixed Exercise Price shall be made
with respect to the issuance of securities by the Company, all of the net
proceeds of which are used to repurchase, in whole or in part, the Notes as
contemplated by Section 4(e) of the Purchase Agreement (an "Exempt Issuance"),
provided that the Holder receives an adjustment to the Fixed Exercise Price to
the extent that any options or warrants are issued in connection with such
Exempt Issuance. For example, if warrants to purchase 10,000 shares of Common
Stock are issued in connection with the Exempt Issuance at a
6
<PAGE>
conversion price of $0.10, then a total of 10,000 of the shares of Common Stock
otherwise issuable to each of the holders of warrants issued in connection with
the Purchase Agreement (including, without limitation, the Holder) at the
exercise price provided for herein shall have a Fixed Exercise Price of $0.10.
As among the holders, the shares of Common Stock issuable to such holders
pursuant to this Section 2.13 shall be allocated among such holders pro rata in
accordance with the respective number of shares of Common Stock otherwise
issuable to the holders pursuant to such warrants.
III. EXERCISE
3.1 EXERCISE OF WARRANT.
(a) The Holder may exercise this Warrant by (i) surrendering this
Warrant Certificate with the form of exercise notice attached hereto as Exhibit
"A" duly executed by the Holder, and (ii) making payment to the Company of the
aggregate Exercise Price for the applicable Warrant Shares in cash, by certified
check or wire transfer of immediately available funds to an account designated
by the Company. Upon any partial exercise of this Warrant, the Company, at its
expense, shall promptly issue to the Holder for its surrendered Warrant
Certificate a replacement Warrant Certificate identical in all respects to this
Warrant Certificate, except that the number of Warrant Shares shall be reduced
accordingly.
(b) Notwithstanding anything in this Warrant to the contrary, in no
event shall the holder of this Warrant be entitled to exercise a number of
Warrants (or portions thereof) in excess of the number of Warrants (or portions
thereof) upon exercise of which the sum of (i) the number of shares of Common
Stock beneficially owned by the holder and its affiliates (other than shares of
Common Stock which may be deemed beneficially owned through the ownership of the
unexercised Warrants and the unexercised or unconverted portion of any other
securities of the Company (including the Notes (as defined in the Securities
Purchase Agreement)) subject to a limitation on conversion or exercise analagous
to the limitation contained herein) and (ii) the number of shares of Common
Stock issuable upon exercise of the Warrants (or portions thereof) with respect
to which the determination described herein is being made, would at the time of
exercise result in beneficial ownership by the holder and its affiliates of more
than 4.9% of the outstanding shares of Common Stock. For purposes of the
immediately preceding sentence, beneficial ownership shall be determined in
accordance with Section 13(d) of the Securities Exchange Act of 1934, as
amended, and Regulation 13D-G thereunder, except as otherwise provided in clause
(i) of the preceding sentence. Notwithstanding anything to the contrary
contained herein, the limitation on exercise of this Warrant set forth herein
may not be amended without (i) the written consent of the holder hereof and the
Company and (ii) the approval of a majority of shareholders of the Company.
(c) Each person in whose name any Warrant Share certificate is issued
upon exercise of this Warrant shall for all purposes been deemed to have become
the holder of record of the Warrant Shares for which this Warrant was exercised
as of the date of exercise. Certificates for the Warrant Shares so purchased,
representing the aggregate number of shares specified in the Exercise Agreement,
shall be delivered to the holder hereof within a reasonable time, not exceeding
three (3) business days, after this Warrant shall have been so exercised. The
certificates so delivered
7
<PAGE>
shall be in such denominations as may be requested by the holder hereof and
shall be registered in the name of such holder or such other name as shall be
designated by such holder. If this Warrant shall have been exercised only in
part, then, unless this Warrant has expired, the Company shall, at its expense,
at the time of delivery of such certificates, deliver to the holder a new
Warrant representing the number of shares with respect to which this Warrant
shall not then have been exercised. In addition to all other available remedies
at law or in equity, if the Company fails to deliver certificates for the
Warrant Shares within four (4) business days after this Warrant is exercised,
then the Company shall pay to the holder in cash a penalty (the "Penalty") equal
to 2% of the number of Warrant Shares that the Holder is entitled to multiplied
by the Market Price for each day that the Company fails to deliver certificates
for the Warrant Shares. For example, if the Holder is entitled to 100,000
Warrant Shares and the Market Price is $2.00, then the Company shall pay to the
Holder $4,000 for each day that the Company fails to deliver certificates for
the Warrant Shares. The Penalty shall be paid to the Holder by the fifth day of
the month following the month in which it has accrued.
3.2 ISSUANCE OF WARRANT SHARES. The Warrant Shares purchased shall be
issued to the Holder exercising this Warrant as of the close of business on the
business day on which all actions and payments required to be taken or made by
the Holder hereunder shall have been so taken or made. Certificates for the
Warrant Shares so purchased shall be delivered to the Holder as soon as
reasonably practicable after this Warrant is so exercised.
3.3 CASHLESS EXERCISE. Notwithstanding any provisions herein to the
contrary, in lieu of exercising this Warrant by paying the Exercise Price in the
manner set forth in Section 3.1(a), prior to its expiration pursuant to Section
1.2, the Holder may, by providing notice thereof to the Company along with the
Notice of Exercise, elect to exercise the Warrant for a reduced number of
Warrant Shares determined in accordance with the following formula:
X = Y(A-B)
------
A
Where:
X = The number of Warrant Shares to be issued to the Holder.
Y = The number of Warrant Shares purchasable under this Warrant (at the
date of such exercise).
A = The fair market value of one share of Common Stock (or other
security for which the Warrant is then exercisable at the date of such
exercise).
B = Exercise Price (as adjusted to the date of such exercise).
For purposes of this Section 3.3, the "fair market value" per share
shall be, in the event the Warrant is being exercised at the time the Company's
Common Stock is listed on a national securities exchange or admitted to unlisted
trading privileges on any such exchange or listed for trading on the Nasdaq
Stock Market, the last reported sale price of Common Stock on such exchange
8
<PAGE>
or system on the last business day prior to the date of exercise of the Warrant
(or if no such sale is made on such day, the average of the closing bid and ask
prices for Common Stock for such day on such exchange or system), or otherwise
shall be determined in such reasonable manner as may be prescribed in good faith
by the Company's Board of Directors.
IV. RIGHTS OF THE HOLDER
4.1 NO RIGHTS OR LIABILITIES AS SHAREHOLDER. Except as provided herein, the
Holder shall not, solely by virtue of this Warrant and prior to the issuance of
the Warrant Shares upon due exercise hereof, be entitled to any rights as a
shareholder of the Company. No provision of this Warrant, in the absence of
affirmative action by the holder hereof to purchase Warrant Shares, and no mere
enumeration herein of the rights or privileges of the holder hereof, shall give
rise to any liability of such holder for the Exercise Price or as a shareholder
of the Company, whether such liability is asserted by the Company or by
creditors of the Company.
4.2 CERTAIN COVENANTS. The Company will (a) take all such action as may be
necessary or appropriate in order that the Warrant Shares will, upon issuance in
accordance with the terms hereof and the payment of the Exercise Price therefor,
be duly authorized, validly issued and outstanding, fully paid and
non-assessable and (b) use its reasonable efforts to obtain all such
authorizations, exemptions or consents from any public regulatory body having
jurisdiction thereof as may be necessary to enable the Company to perform its
obligations under this Warrant. The Company will not, by amendment of its
charter or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities, or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms to be
observed or performed by it hereunder, but will at all times in good faith
assist in the carrying out of all the provisions of this Warrant and in the
taking of all such action as may reasonably be requested by the holder of this
Warrant in order to protect the exercise privilege of the holder of this Warrant
against dilution or other impairment, consistent with the tenor and purpose of
this Warrant. Without limiting the generality of the foregoing, the Company (i)
will not increase the par value of any shares of Common Stock receivable upon
the exercise of this Warrant above the Exercise Price then in effect, and (ii)
will take all such actions as may be necessary or appropriate in order that the
Company may validly and legally issue fully paid and nonassessable shares of
Common Stock upon the exercise of this Warrant in accordance with the terms
hereof and payment of the Exercise Price therefor.
9
<PAGE>
V. LOSS
Upon receipt by the Company of evidence reasonably satisfactory to it of
the loss, theft, destruction or mutilation of this Warrant, and (in the case of
loss, theft or destruction) reasonably satisfactory indemnification, and upon
surrender and cancellation of this Warrant, if mutilated, the Company shall
immediately execute and deliver a new Warrant of like tenor and date.
VI. LEGEND ON WARRANT SHARES
6.1 LEGEND. The certificates representing the Warrant Shares shall bear a
legend substantially similar to the following:
"The securities represented by this certificate have not been
registered under the Securities Act of 1933, as amended (the "Act") or
under applicable state securities laws, and may not be offered or sold
except (1) pursuant to an effective registration statement under the
Act or (2) upon the delivery by the holder to the Company of an opinion
of counsel reasonably satisfactory to the Company that such
registration statement is not required under the Securities Act and the
rules and regulations promulgated thereunder or under applicable state
securities laws."
VII. REGISTRATION RIGHTS
7.1 REGISTRATION RIGHTS AGREEMENT. The Holder shall be entitled to
registration rights pursuant to the terms of that certain Registration Rights
Agreement between the Company and the signatories thereto (the "Registration
Rights Agreement") of even date herewith.
7.2 EXCHANGE AGREEMENT. Upon consummation of the Exchange Agreement, all
obligations of the Company under the Registration Rights Agreement shall become
obligations of Cytomedix NV.
7.3 FAILURE TO MEET OBLIGATIONS. If the Company shall fail to prepare and
file the Registration Statement (as defined in the Registration Rights
Agreement) within forty-five (45) days of the date hereof, then the Fixed
Exercise Price shall be reduced to $0.01 per Warrant Share.
VIII. MISCELLANEOUS
8.1 REPRESENTATIONS OF THE COMPANY. The Company represents and warrants to
the Holder as follows:
(a) The execution and delivery of this Warrant and the performance by
the Company of its obligations hereunder have been duly authorized by all
necessary corporate action on part of the Company in accordance with its Bylaws
and Articles of Incorporation.
(b) This Warrant has been duly executed and delivered by the Company
and constitutes the legal, valid, binding and enforceable obligation of the
Company, enforceable in
10
<PAGE>
accordance with its terms, except as such enforceability may be limited by
applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or
similar laws relating to, or affecting generally, the enforcement of creditors'
rights and remedies or by other equitable principles of general application.
(c) Upon issuance thereof in accordance with the terms hereof and
payment of the Exercise Price therefor, all of the Shares will, upon issuance,
be duly authorized, validly issued and outstanding, fully paid and
non-assessable, and free from all taxes, liens and charges with respect to the
issuance thereof.
(d) Except for filings under applicable state and federal securities
laws, the Company has obtained all such authorizations, exemptions or consents
from any public regulatory body having jurisdiction thereof as may be necessary
to enable the Company to perform its obligations hereunder.
(e) There are no state statutes or other "anti-takeover" laws
applicable to the Company, to the issuance of this Warrant by the Company, or to
the issuance of the Warrant Shares upon exercise of this Warrant which would
have, among other things, the effect of nullifying the transactions contemplated
by this Warrant, or affecting the Holder's voting rights or other rights as a
shareholder following such exercise, or to the extent there are such applicable
state statutes or other "anti-takeover" laws, the Company and its Board of
Directors have taken all steps necessary under such statutes or laws to render
them inapplicable to the Company, the issuance of this Warrant, and the issuance
of the Warrant Shares upon exercise of this Warrant.
(f) There is no litigation pending, or, to the knowledge of the
Company, threatened, against the Company which, if adversely decided or
resolved, would have a Material Adverse Effect, as defined in the Purchase
Agreement.
8.2 ASSIGNMENT. The rights, obligations and duties of the Company hereunder
shall not be assignable or otherwise transferable by the Company. This Warrant
and the rights granted to the holder hereof are transferable by the Holder, in
whole or in part, upon surrender of this Warrant, together with a properly
executed assignment in the form attached hereto, at the office or agency of the
Company.
If, at the time of the surrender of this Warrant in connection with any
exercise, transfer, or exchange of this Warrant, this Warrant (or, in the case
of any exercise, the Warrant Shares issuable hereunder), shall not be registered
under the Securities Act of 1933, as amended (the "Securities Act") and under
applicable state securities or blue sky laws, the Company may require, as a
condition of allowing such exercise, transfer, or exchange, (i) that the holder
or transferee of this Warrant, as the case may be, furnish to the Company a
written opinion of counsel, which opinion and counsel are acceptable to the
Company, to the effect that such exercise, transfer, or exchange may be made
without registration under said Act and under applicable state securities or
blue sky laws, (ii) that the holder or transferee execute and deliver to the
Company an investment letter in form and substance acceptable to the Company and
(iii) that the transferee be an "accredited investor" as defined in Rule 501(a)
of Regulation D promulgated
11
<PAGE>
under the Securities Act; provided that no such opinion, letter or status as an
"accredited investor" shall be required in connection with a transfer pursuant
to Rule 144 under the Securities Act. The first holder of this Warrant, by
taking and holding the same, represents to the Company that such holder is
acquiring this Warrant for investment and not with a view to the distribution
thereof.
8.3 MODIFICATION. No term or provision contained herein may be
modified, amended or waived except by written agreement or consent signed by the
party to be bound thereby.
8.4 BINDING EFFECT AND BENEFIT. This warrant shall inure to the benefit
of, and shall be binding upon, the parties hereto, their heirs, executors,
administrators, personal representatives, successors in interest and permitted
assigns.
8.5 ATTORNEYS' FEES. In the event the Holder shall employ legal counsel
to protect its rights hereunder or to enforce any term or provision hereof or
under any of the Loan Documents (as defined in the "Note"), such reasonable
attorneys' fees and other legal expenses shall be payable by Company to the
Holder upon demand. The Company shall pay all fees and expenses of the Holder in
connection with the negotiation and consummation of this Warrant and the Loan
Documents.
8.6 FURTHER ASSURANCES. Company agrees that from time to time
hereafter, upon request, it will, at its sole expense, execute, acknowledge and
deliver such other instruments and documents and take such further action as may
be reasonably necessary to carry out the intent of this warrant and the Loan
Documents.
8.7 GOVERNING LAW; WAIVER OF JURY TRIAL. THIS WARRANT SHALL BE
INTERPRETED, AND THE RIGHTS AND LIABILITIES OF THE PARTIES HERETO DETERMINED, IN
ACCORDANCE WITH THE INTERNAL LAWS (AS OPPOSED TO CONFLICTS OF LAW PROVISIONS) OF
THE STATE OF ILLINOIS. AS PART OF THE CONSIDERATION FOR NEW VALUE THIS DAY
RECEIVED, THE COMPANY HEREBY CONSENTS TO THE JURISDICTION OF ANY STATE OR
FEDERAL COURT LOCATED IN CHICAGO, ILLINOIS. EACH OF THE COMPANY AND THE HOLDER
HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES TRIAL BY JURY IN ANY SUIT OR
PROCEEDING ARISING OUT OF OR RELATED TO THIS WARRANT OR THE OTHER LOAN
DOCUMENTS. THE COMPANY WAIVES ANY OBJECTION WHICH THE COMPANY MAY HAVE BASED ON
LACK OF JURISDICTION OR IMPROPER VENUE OR FORUM NON CONVENIENS TO ANY SUIT OR
PROCEEDING INSTITUTED BY THE HOLDER UNDER THIS WARRANT OR THE OTHER LOAN
DOCUMENTS IN ANY STATE OR FEDERAL COURT LOCATED IN CHICAGO, ILLINOIS AND
CONSENTS TO THE GRANTING OF SUCH LEGAL OR EQUITABLE RELIEF AS IS DEEMED
APPROPRIATE BY THE COURT. NOTHING IN THIS SECTION SHALL AFFECT THE RIGHT OF THE
HOLDER TO BRING ANY ACTION OR PROCEEDING AGAINST THE COMPANY OR ITS PROPERTY IN
THE COURTS OF ANY OTHER JURISDICTION WHICH HAS JURISDICTION OVER THE COMPANY OR
ITS PROPERTY. THIS PROVISION IS A MATERIAL INDUCEMENT FOR THE HOLDER TO ENTER
INTO THIS WARRANT AND THE OTHER LOAN DOCUMENTS,
12
<PAGE>
MAKE THE LOANS AND EXTEND THE OTHER FINANCIAL ACCOMMODATIONS CONTEMPLATED
HEREUNDER AND THEREUNDER.
8.8 INCORPORATION BY REFERENCE. All exhibits and documents referred to
in this agreement shall be deemed incorporated herein by any reference thereto
as if fully set out.
8.9 COUNTERPARTS. This agreement may be executed in one or more
counterparts (all counterparts together reflecting the signature of all parties)
each of which shall be deemed an original, and all of which together shall
constitute one and the same instrument.
8.10 CONSENT TO JURISDICTION AND SERVICE OF PROCESS. Company hereby
irrevocably (i) consents to the jurisdiction of the courts of the State of
Illinois and of any federal court located in Illinois in connection with any
action or proceeding arising out of or relating to this agreement, or any other
document or exhibit relating hereto or delivered in connection therewith and
(ii) consents that service of legal process in any such action or proceeding may
be made in any manner permitted by the rules of practice and procedure
applicable to such courts.
8.11 INDEMNIFICATION OF THE HOLDER. From and at all times after the
date of this Warrant, and in addition to all of the Holder's other rights and
remedies against the Company, the Company agrees to hold the Holder harmless
from, and to indemnify the Holder against, all losses, damages, costs and
expenses (including, but not limited to, attorneys' fees, costs and expenses)
incurred by the Holder from and after the date hereof, whether direct, indirect
or consequential, as a result of or arising from or relating to any suit, action
or proceeding by any Person, whether threatened or initiated, asserting a claim
for any legal or equitable remedy against any Person under any statute or
regulation, including, but not limited to, any federal or state securities laws,
or under any common law or equitable cause or otherwise, arising from or in
connection with the negotiation, preparation, execution or performance of, this
Warrant and the other Loan Documents; provided, however, that the foregoing
indemnification shall not protect Holder from loss, damage, cost or expense
directly attributable to Holder's willful misconduct or gross negligence. All of
the foregoing losses, damages, costs and expenses of the Holder shall be payable
by the Company upon demand by the Holder.
8.12 SURVIVAL OF AGREEMENTS. All agreements, covenants, representations
and warranties contained herein or made in writing by or on behalf of the
Company in connection with the transactions contemplated hereby shall survive
the execution and delivery of this Warrant and the other Loan Documents.
8.13 HEADINGS AND CAPTIONS. Subject headings and captions are included
for convenience purposes only and shall not affect the interpretation of this
agreement.
8.14 NOTICE. All notices, requests, demands and other communications
permitted or required hereunder shall be in writing, and either (i) delivered in
person, (ii) sent by express mail or other overnight delivery service providing
receipt of delivery, (iii) mailed by certified or registered mail, postage
prepaid, return receipt requested or (iv) sent by telex, telegraph or other
facsimile transmission as follows:
13
<PAGE>
If to Company addressed or delivered in person to:
Cytomedix, Inc.
Three Parkway North, Suite 250 North
Deerfield, IL 60015
Attention: President
Telephone: 847-405-7800
Facsimile: 847-405-7801
With a copy to:
Latham & Watkins
1001 Pennsylvania Avenue, N.W.
Suite 1300
Washington, DC 20004-2505
Attention: Stuart Kurlander, Esq.
Telephone: 202-637-2200
Facsimile: 202-637-2201
If to the Holder, addressed or delivered in person to:
Curative Health Services, Inc.
150 Motor Parkway
Happaugue, New York 11788
Attention: William Tella
Sr. Vice President of Business Development
Telephone: 631-232-7000
Facsimile: 631-233-8102
With a copy to:
Dorsey & Whitney LLP
250 Park Avenue
New York, New York 10177
Attention: Seth Truwit, Esq.
Telephone: 212-415-9200
Facsimile: 212-953-7201
or to such other address as either party may designate by notice in accordance
with this Section.
Any such notice or communication, if given or made by prepaid,
registered or certified mail or by recorded express delivery, shall be deemed to
have been made when actually received, but not later than three (3) business
days after the same was properly posted or given to
14
<PAGE>
such express delivery service and if made properly by telex, telecopy or other
facsimile transmission such notice or communication shall be deemed to have been
made at the time of dispatch.
8.15 SEVERABILITY. If any portion of this agreement is held invalid,
illegal or unenforceable, such determination shall not impair the enforceability
of the remaining terms and provisions herein, which may remain effective, and to
this end this agreement is declared to be severable.
8.16 TIME FOR PERFORMANCE. Time is of the essence in this agreement.
8.17 WAIVER. No waiver of a default, breach or other violation of any
provision of this agreement shall operate or be construed as a waiver of any
subsequent default, breach or other violation or limit or restrict any right or
remedy otherwise available. No delay or omission on the part of the Holder to
exercise any right or power arising by reason of a default shall impair any such
right or power or prevent its exercise at any time during the continuance
thereof.
8.18 GENDER AND PRONOUNS. Throughout this agreement, the masculine shall
include the feminine and neuter and the singular shall include the plural and
vice versa as the context requires.
8.19 ENTIRE AGREEMENT. This Warrant and the Loan Documents constitute the
entire agreement of the parties and supersede any and all other prior
agreements, oral or written, with respect to the subject matter contained
herein.
8.20 REMEDIES. The Company acknowledges that a breach by it of its
obligations hereunder will cause irreparable harm to the holder, by vitiating
the intent and purpose of the transaction contemplated hereby. Accordingly, the
Company acknowledges that the remedy at law for a breach of its obligations
under this Warrant will be inadequate and agrees, in the event of a breach or
threatened breach by the Company of the provisions of this Warrant, that the
holder shall be entitled, in addition to all other available remedies at law or
in equity, and in addition to the penalties assessable herein, to an injunction
or injunctions restraining, preventing or curing any breach of this Warrant and
to enforce specifically the terms and provisions thereof, without the necessity
of showing economic loss and without any bond or other security being required.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
15
<PAGE>
IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed
and delivered as of the 26th day of December, 2000.
CYTOMEDIX, INC.
By: /s/ Robin Lee Geller
------------------------------------
Name: Robin Lee Geller
Title: Vice President
ATTEST:
/s/ David C. Demarest
---------------------------
16
<PAGE>
EXHIBIT A
---------
EXERCISE NOTICE
[To be executed only upon exercise of Warrant]
The undersigned registered owner of this Warrant irrevocably exercises
this Warrant for the purchase of the number of shares of Common Stock of
Cytomedix, Inc. as is set forth below, and herewith makes payment therefor, all
at the price and on the terms and conditions specified in the attached Warrant
Certificate and requests that certificates for the shares of Common Stock hereby
purchased (and any securities or other property issuable upon such exercise) be
issued in the name of and delivered to the person specified below whose address
is set forth below, and, if such shares of Common Stock shall not include all of
the shares of Common Stock now and hereafter issuable as provided in the
attached Warrant Certificate, then Cytomedix, Inc. shall, at its own expense,
promptly issue to the undersigned a new Warrant Certificate of like tenor and
date for the balance of the shares of Common Stock issuable thereunder.
Date:
--------------------
Amount of Shares Purchased:
------------------
Aggregate Purchase Price: $
------------------
Printed Name of Registered Holder:
---------------------------------
Signature of Registered Holder:
------------------------------------
NOTICE: The signature on this Exercise Notice must correspond with the name as
written upon the face of the attached Warrant Certificate in every
particular, without alteration or enlargement or any change whatsoever.
Stock Certificates to be issued and registered in the following name, and
delivered to the following address:
-----------------------------------
(Name)
-----------------------------------
(Street Address)
-----------------------------------
(City) (State) (Zip Code)
17
<PAGE>
ASSIGNMENT
FOR VALUE RECEIVED, the undersigned hereby sells, assigns, and
transfers all the rights of the undersigned under the within Warrant, with
respect to the number of shares of Common Stock covered thereby set forth
hereinbelow, to:
Name of Assignee Address No of Shares
---------------- ------- ------------
, and hereby irrevocably constitutes and appoints ____________________________as
agent and attorney-in-fact to transfer said Warrant on the books of the
within-named corporation, with full power of substitution in the premises.
Dated: , 200
----------- --- --
In the presence of:
----------------------------------
Name:
----------------------------------
Signature:
-----------------------------
Title of Signing Officer or Agent (if any):
-----------------------------
Address:
-------------------------------
-------------------------------
Note: The above signature should
correspond exactly with the name
on the face of the within
Warrant, if applicable.
18
